<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01930188</url>
  </required_header>
  <id_info>
    <org_study_id>NN9535-3626</org_study_id>
    <secondary_id>2012-004827-19</secondary_id>
    <secondary_id>U1111-1135-8730</secondary_id>
    <secondary_id>132366</secondary_id>
    <secondary_id>CTRI/2014/05/004626</secondary_id>
    <nct_id>NCT01930188</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes</brief_title>
  <acronym>SUSTAIN™ 2</acronym>
  <official_title>Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN™ 2 - vs. DPP-4 Inhibitor)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Africa, Asia, Europe and South America. The aim of the trial is to
      evaluate efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as
      add-on to metformin and/or TZD (thiazolidinedione) in subjects with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2, 2013</start_date>
  <completion_date type="Actual">October 12, 2015</completion_date>
  <primary_completion_date type="Actual">October 12, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c (Glycosylated Haemoglobin) From Baseline</measure>
    <time_frame>Week 0, week 56</time_frame>
    <description>Change in HbA1c from baseline until week 56.Full analysis set (FAS=1225) included all randomised subjects who had received at least one dose of randomised semaglutide or sitagliptin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight From Baseline</measure>
    <time_frame>Week 0, week 56</time_frame>
    <description>Change in body weight from baseline to week 56. Full analysis set (FAS=1225) included all randomised subjects who had received at least one dose of semaglutide or sitagliptin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (FPG) From Baseline</measure>
    <time_frame>Week 0, week 56</time_frame>
    <description>Change in fasting plasma glucose from baseline to week 56. Full analysis set (FAS=1225) included all randomised subjects who had received at least one dose of semaglutide or sitagliptin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic and Diastolic Blood Pressure From Baseline</measure>
    <time_frame>Week 0, week 56</time_frame>
    <description>Change in systolic and diastolic blood pressure from baseline to week 56. Full analysis set (FAS=1225) included all randomised subjects who had received at least one dose of semaglutide or sitagliptin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Reported Outcome (PRO) Questionnaire Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) From Baseline</measure>
    <time_frame>Week 0, week 56</time_frame>
    <description>Full analysis set (FAS=1225) included all randomised subjects who had received at least one dose of semaglutide or sitagliptin. The DTSQs questionnaire was used to assess subjects' treatment satisfaction. This questionnaire contained 8 components and evaluates the diabetes treatment (including insulin, tablets and/or diet) in terms of convenience, flexibility and general feelings towards the treatment. The result presented is the 'Treatment Satisfaction' summary score, which is the sum of 6 of the 8 items of the DTSQs questionnaire. Response options range from 6 (best case) to 0 (worst case). Total scores for treatment satisfaction range from 0-36. Higher scores indicate higher satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Who Achieved HbA1c Below or Equal to 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists (AACE) Target (Yes/no)</measure>
    <time_frame>After 56 weeks treatment</time_frame>
    <description>Subjects who achieved HbA1c ≤6.5% (48 mmol/mol) American Association of Clinical Endocrinologists (AACE) target (yes/no) after week 56 weeks of treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1231</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Semaglutide 0.5 mg + sitagliptin placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide 1.0 mg + sitagliptin placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg + semaglutide placebo 1.0 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg + semaglutide placebo 0.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.</description>
    <arm_group_label>Semaglutide 0.5 mg + sitagliptin placebo</arm_group_label>
    <arm_group_label>Semaglutide 1.0 mg + sitagliptin placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin</intervention_name>
    <description>Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.</description>
    <arm_group_label>Sitagliptin 100 mg + semaglutide placebo 0.5 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg + semaglutide placebo 1.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.</description>
    <arm_group_label>Semaglutide 0.5 mg + sitagliptin placebo</arm_group_label>
    <arm_group_label>Semaglutide 1.0 mg + sitagliptin placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.</description>
    <arm_group_label>Sitagliptin 100 mg + semaglutide placebo 0.5 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg + semaglutide placebo 1.0 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Japan: Age minimum 20 years - Subjects diagnosed with type 2 diabetes
        and on stable treatment in a period of 90 days prior to screening with either metformin
        above or equal to 1500 mg (or maximum tolerated dose), pioglitazone above or equal to 30 mg
        (or maximum tolerated dose), rosiglitazone above or equal to 4 mg (or maximum tolerated
        dose) or a combination of either metformin/pioglitazone or metformin/rosiglitazone (doses
        as for individual therapies). Stable is defined as unchanged medication and unchanged dose
        - HbA1c 7.0 - 10.5 % (53 - 91 mmol/mol) (both inclusive) Exclusion Criteria: - Females of
        childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are
        not using an adequate contraceptive method throughout the trial including the 5 weeks
        follow-up period (adequate contraceptive measures as required by local law or practice) -
        Any chronic disorder or severe disease which, in the opinion of the investigator, might
        jeopardise subject's safety or compliance with the protocol - Treatment with glucose
        lowering agent(s) other than stated in the inclusion criteria in a period of 90 days before
        screening. An exception is short-term treatment (below or equal to 7 days in total) with
        insulin in connection with inter-current illness - History of chronic or idiopathic acute
        pancreatitis - Screening calcitonin value above or equal to 50 ng/L (pg/mL) - Personal or
        family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia
        syndrome type 2 (MEN 2) - Impaired renal function defined as estimated glomerular
        filtration rate (eGFR) below 60 ml/min/1.73 m2 per modification of diet in renal disease
        (MDRD) formula (4 variable version) - Acute coronary or cerebrovascular event within 90
        days before randomisation - Heart failure, New York Heart Association (NYHA) class IV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425AGC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Caba</city>
        <zip>C1179AAB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mar del Plata</city>
        <zip>B7600GNY</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Burgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Haskovo</city>
        <zip>6300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Petrich</city>
        <zip>2850</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ruse</city>
        <zip>7000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sliven</city>
        <zip>8800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Smolyan</city>
        <zip>4700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1336</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Vratsa</city>
        <zip>3001</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chrudim</city>
        <zip>537 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ostrava</city>
        <zip>707 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Plzen</city>
        <zip>304 60</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Praha 4- Chodov</city>
        <zip>149 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Praha 5</city>
        <zip>150 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Shatin, New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1076</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>H-1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4043</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Szeged</city>
        <zip>H-6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Szombathely</city>
        <zip>H-9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kochi</city>
        <state>Kerala</state>
        <zip>682041</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kozhikode</city>
        <state>Kerala</state>
        <zip>673017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Trivandrum</city>
        <state>Kerala</state>
        <zip>695011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Indore</city>
        <state>Madhya Pradesh</state>
        <zip>452010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411040</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Orissa</state>
        <zip>751019</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ludhiana</city>
        <state>Punjab</state>
        <zip>141001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600116</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Asahikawa-shi, Hokkaido</city>
        <zip>070-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ibaraki</city>
        <zip>311-0113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kashiwara-shi, Osaka</city>
        <zip>582-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kitakyushu-shi, Fukuoka</city>
        <zip>800 0252</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mitaka-shi, Tokyo</city>
        <zip>181-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mito-shi, Ibaraki</city>
        <zip>310-0826</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Miyazaki</city>
        <zip>880-0034</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Okayama-shi, Okayama</city>
        <zip>700 8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Osaka-shi, Osaka</city>
        <zip>532 0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Osaka-shi, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>569-1045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sapporo-shi, Hokkaido</city>
        <zip>060-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>125-0054</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pachuca</city>
        <state>Hidalgo</state>
        <zip>42084</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44670</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64620</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20129</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamar</city>
        <zip>2317</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kløfta</city>
        <zip>2040</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kongsvinger</city>
        <zip>2212</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Stavanger</city>
        <zip>4005</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ålesund</city>
        <zip>6003</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Almada</city>
        <zip>2805-267</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3046-853</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1250-230</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1500-650</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Matosinhos</city>
        <zip>4464-513</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tomar</city>
        <zip>2304-909</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Viana do Castelo</city>
        <zip>4901-858</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Vila Nova de Gaia</city>
        <zip>4434-502</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Baia Mare</city>
        <state>Maramures</state>
        <zip>430123</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ploiesti</city>
        <state>Prahova</state>
        <zip>100342</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Brasov</city>
        <zip>500365</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>020359</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>022441</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Barnaul</city>
        <zip>656024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>119435</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197762</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Samara</city>
        <zip>443041</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saratov</city>
        <zip>410018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tumen</city>
        <zip>625023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ufa</city>
        <zip>450083</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Volgograd</city>
        <zip>400138</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Voronezh</city>
        <zip>394018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>East London</city>
        <state>Eastern Cape</state>
        <zip>5201</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Krugersdorp</city>
        <state>Gauteng</state>
        <zip>1739</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0084</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4092</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Almería</city>
        <zip>04001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Centelles (Barcelona)</city>
        <zip>08540</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>La Roca del Vallés</city>
        <zip>08430</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kristianstad</city>
        <zip>291 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lund</city>
        <zip>222 22</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Malmö</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>113 24</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bangkoknoi, Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nakhon Ratchasima</city>
        <zip>30000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ankara</city>
        <zip>06110</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Antalya</city>
        <zip>07058</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34303</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34371</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34718</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34752</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34890</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Konya</city>
        <zip>42090</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rize</city>
        <zip>53020</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Trabzon</city>
        <zip>61040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Çorum</city>
        <zip>19200</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cherkasy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Odesa</city>
        <zip>65114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Zaporizhia</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <reference>
    <citation>Fonseca VA, Capehorn MS, Garg SK, Jódar Gimeno E, Hansen OH, Holst AG, Nayak G, Seufert J. Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide. J Clin Endocrinol Metab. 2019 Apr 2. pii: jc.2018-02685. doi: 10.1210/jc.2018-02685. [Epub ahead of print] Erratum in: J Clin Endocrinol Metab. 2020 Jan 1;105(1):.</citation>
    <PMID>30938762</PMID>
  </reference>
  <reference>
    <citation>Rodbard HW, Bellary S, Hramiak I, Seino Y, Silver R, Damgaard LH, Nayak G, Zacho J, Aroda VR. GREATER COMBINED REDUCTIONS IN HbA(1C) ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES. Endocr Pract. 2019 Jun;25(6):589-597. doi: 10.4158/EP-2018-0444. Epub 2019 Mar 13.</citation>
    <PMID>30865526</PMID>
  </reference>
  <results_reference>
    <citation>Ahrén B, Comas LM, Kumar H, Sargin M, Derving Karsbøl J, Jacobsen SH, Chow F. Efficacy and Safety of Once-weekly Semaglutide vs Sitagliptin as add-on to Metformin and/or Thiazolidinediones After 56 Weeks in Subjects With Type 2 Diabetes (SUSTAIN 2). Oral Presentation 12 Jun 2016 at American Diabetes Association - 76th Annual Scientific Sessions.</citation>
  </results_reference>
  <results_reference>
    <citation>Ahrén B, Masmiquel L, Kumar H, Sargin M, Derving Karsbøl J, Jacobsen SH, Chow F. Efficacy and Safety of Once-weekly Semaglutide vs Sitagliptin as add-on to Metformin and/or Thiazolidinediones After 56 Weeks in Subjects With Type 2 Diabetes (SUSTAIN 2). ePoster #767 presented 12 Sep 2016 at European Association for the Study of Diabetes - 52nd Annual Meeting.</citation>
  </results_reference>
  <results_reference>
    <citation>Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, Chow F. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017 May;5(5):341-354. doi: 10.1016/S2213-8587(17)30092-X. Epub 2017 Apr 3.</citation>
    <PMID>28385659</PMID>
  </results_reference>
  <results_reference>
    <citation>Petri KCC, Ingwersen SH, Flint A, Zacho J, Overgaard RV. Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes. Diabetes Obes Metab. 2018 Sep;20(9):2238-2245. doi: 10.1111/dom.13358. Epub 2018 Jun 15.</citation>
    <PMID>29748996</PMID>
  </results_reference>
  <results_reference>
    <citation>Ahrén B, Atkin SL, Charpentier G, Warren ML, Wilding JPH, Birch S, Holst AG, Leiter LA. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes Obes Metab. 2018 Sep;20(9):2210-2219. doi: 10.1111/dom.13353. Epub 2018 Jun 12.</citation>
    <PMID>29766634</PMID>
  </results_reference>
  <results_reference>
    <citation>Sharma R, Wilkinson L, Vrazic H, Popoff E, Lopes S, Kanters S, Druyts E. Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis. Curr Med Res Opin. 2018 Sep;34(9):1595-1603. doi: 10.1080/03007995.2018.1476332. Epub 2018 May 29.</citation>
    <PMID>29764222</PMID>
  </results_reference>
  <results_reference>
    <citation>DeVries JH, Desouza C, Bellary S, Unger J, Hansen OKH, Zacho J, Woo V. Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme. Diabetes Obes Metab. 2018 Oct;20(10):2426-2434. doi: 10.1111/dom.13396. Epub 2018 Jul 9.</citation>
    <PMID>29862621</PMID>
  </results_reference>
  <results_reference>
    <citation>Carlsson Petri KC, Ingwersen SH, Flint A, Zacho J, Overgaard RV. Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis. Diabetes Ther. 2018 Aug;9(4):1533-1547. doi: 10.1007/s13300-018-0458-5. Epub 2018 Jun 15.</citation>
    <PMID>29907893</PMID>
  </results_reference>
  <results_reference>
    <citation>Aroda VR, Ahmann A, Cariou B, Chow F, Davies MJ, Jódar E, Mehta R, Woo V, Lingvay I. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes Metab. 2019 Oct;45(5):409-418. doi: 10.1016/j.diabet.2018.12.001. Epub 2019 Jan 4. Review.</citation>
    <PMID>30615985</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>August 23, 2013</study_first_submitted>
  <study_first_submitted_qc>August 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2013</study_first_posted>
  <results_first_submitted>December 14, 2017</results_first_submitted>
  <results_first_submitted_qc>June 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 7, 2019</results_first_posted>
  <disposition_first_submitted>November 10, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>November 10, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 11, 2016</disposition_first_posted>
  <last_update_submitted>May 28, 2019</last_update_submitted>
  <last_update_submitted_qc>May 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted at 124 sites in 18 countries: Argentina: 4; Bulgaria: 10; Czech Republic: 5; Hong Kong: 1; Hungary: 4; India: 11; Japan: 14; Mexico: 5 Norway: 5; Portugal: 6; Romania: 5; Russian Federation: 17; South Africa: 7; Spain: 7: Sweden: 4; Thailand: 4; Turkey: 9; and Ukraine: 6 sites.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Semaglutide 0.5 mg + Sitagliptin Placebo</title>
          <description>Semaglutide 0.5 mg administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin placebo (0 mg) administered orally once daily.</description>
        </group>
        <group group_id="P2">
          <title>Semaglutide 1.0 mg + Sitagliptin Placebo</title>
          <description>Semaglutide 1.0 mg administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin placebo (0 mg) administered orally once daily.</description>
        </group>
        <group group_id="P3">
          <title>Sitagliptin + Semaglutide Placebo</title>
          <description>Subjects were randomised to 2 different placebo arms (sitagliptin + semaglutide placebo 0.5 mg and sitagliptin + semaglutide placebo 1.0 mg). Both arms were pooled together for data analysis. Semaglutide placebo administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin (100 mg) administered orally once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="409"/>
                <participants group_id="P2" count="409"/>
                <participants group_id="P3" count="407"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Premature Discontinuation of Treatment</title>
              <participants_list>
                <participants group_id="P1" count="53">Subjects prematurely discontinued treatment were allowed to continue participation in the trial.</participants>
                <participants group_id="P2" count="61">Subjects prematurely discontinued treatment were allowed to continue participation in the trial.</participants>
                <participants group_id="P3" count="32">Subjects prematurely discontinued treatment were allowed to continue participation in the trial.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="387"/>
                <participants group_id="P2" count="388"/>
                <participants group_id="P3" count="388"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>unclassified</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing follow-up information</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Of 1231 randomised subjects, 6 were excluded: 1 subject each in the semaglutide 0.5 mg and 1.0 mg arms and 4 subjects in the sitagliptin arm were not exposed to trial treatment. Baseline characteristics were presented for 1225 subjects (Full Analysis Set), who received at least one dose of randomised semaglutide or sitagliptin.</population>
      <group_list>
        <group group_id="B1">
          <title>Semaglutide 0.5 mg + Sitagliptin Placebo</title>
          <description>Semaglutide 0.5 mg administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin placebo (0 mg) administered orally once daily.</description>
        </group>
        <group group_id="B2">
          <title>Semaglutide 1.0 mg + Sitagliptin Placebo</title>
          <description>Semaglutide 1.0 mg administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin placebo (0 mg) administered orally once daily.</description>
        </group>
        <group group_id="B3">
          <title>Sitagliptin + Semaglutide Placebo</title>
          <description>Subjects were randomised to 2 different placebo arms (sitagliptin + semaglutide placebo 0.5 mg and sitagliptin + semaglutide placebo 1.0 mg). Both arms were pooled together for data analysis. Semaglutide placebo administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin (100 mg) administered orally once daily.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="409"/>
            <count group_id="B2" value="409"/>
            <count group_id="B3" value="407"/>
            <count group_id="B4" value="1225"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.8" spread="10.2"/>
                    <measurement group_id="B2" value="56.0" spread="9.4"/>
                    <measurement group_id="B3" value="54.6" spread="10.4"/>
                    <measurement group_id="B4" value="55.1" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="204"/>
                    <measurement group_id="B3" value="199"/>
                    <measurement group_id="B4" value="605"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="205"/>
                    <measurement group_id="B3" value="208"/>
                    <measurement group_id="B4" value="620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.01" spread="0.92"/>
                    <measurement group_id="B2" value="8.04" spread="0.93"/>
                    <measurement group_id="B3" value="8.17" spread="0.92"/>
                    <measurement group_id="B4" value="8.07" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89.93" spread="20.39"/>
                    <measurement group_id="B2" value="89.21" spread="20.74"/>
                    <measurement group_id="B3" value="89.29" spread="19.67"/>
                    <measurement group_id="B4" value="89.48" spread="20.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.33" spread="2.38"/>
                    <measurement group_id="B2" value="9.29" spread="2.22"/>
                    <measurement group_id="B3" value="9.60" spread="2.16"/>
                    <measurement group_id="B4" value="9.40" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic and Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Diastolic Blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.63" spread="9.76"/>
                    <measurement group_id="B2" value="80.87" spread="9.08"/>
                    <measurement group_id="B3" value="80.48" spread="8.70"/>
                    <measurement group_id="B4" value="80.66" spread="9.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132.73" spread="16.09"/>
                    <measurement group_id="B2" value="132.56" spread="13.93"/>
                    <measurement group_id="B3" value="132.66" spread="14.58"/>
                    <measurement group_id="B4" value="132.65" spread="14.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in HbA1c (Glycosylated Haemoglobin) From Baseline</title>
        <description>Change in HbA1c from baseline until week 56.Full analysis set (FAS=1225) included all randomised subjects who had received at least one dose of randomised semaglutide or sitagliptin.</description>
        <time_frame>Week 0, week 56</time_frame>
        <population>Missing data imputed from a mixed model for repeated measurements for treatment and country as fixed factors and baseline value as covariate, all nested within visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.5 mg + Sitagliptin Placebo</title>
            <description>Semaglutide 0.5 mg administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin placebo (0 mg) administered orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 1.0 mg + Sitagliptin Placebo</title>
            <description>Semaglutide 1.0 mg administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin placebo (0 mg) administered orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin + Semaglutide Placebo</title>
            <description>Subjects were randomised to 2 different placebo arms (sitagliptin + semaglutide placebo 0.5 mg and sitagliptin + semaglutide placebo 1.0 mg). Both arms were pooled together for data analysis. Semaglutide placebo administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin (100 mg) administered orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c (Glycosylated Haemoglobin) From Baseline</title>
          <description>Change in HbA1c from baseline until week 56.Full analysis set (FAS=1225) included all randomised subjects who had received at least one dose of randomised semaglutide or sitagliptin.</description>
          <population>Missing data imputed from a mixed model for repeated measurements for treatment and country as fixed factors and baseline value as covariate, all nested within visit.</population>
          <units>percentage of glycosylated haemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="409"/>
                <count group_id="O2" value="409"/>
                <count group_id="O3" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.32" spread="0.05"/>
                    <measurement group_id="O2" value="-1.61" spread="0.05"/>
                    <measurement group_id="O3" value="-0.55" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was concluded if the upper limit of the two-sided 95% confidence interval for the estimated treatment difference between semaglutide 1.0 mg and sitagliptin was below the pre-specified non-inferiority margin (0.3 %).</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Post-baseline responses analysed with mixed model for repeated measurements-treatment &amp; country (fixed) &amp; baseline (covariate) all nested within visit</method_desc>
            <param_type>treatment difference</param_type>
            <param_value>-1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.21</ci_lower_limit>
            <ci_upper_limit>-0.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was concluded if the upper limit of the two-sided 95% confidence interval for the estimated treatment difference between semaglutide 0.5 mg and sitagliptin was below the pre-specified non-inferiority margin (0.3 %).</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Analysis done with mixed model for repeated measurements (treatment &amp; country as fixed factors &amp; baseline value as covariate) all nested within visit</method_desc>
            <param_type>treatment difference</param_type>
            <param_value>-0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.21</ci_lower_limit>
            <ci_upper_limit>-0.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight From Baseline</title>
        <description>Change in body weight from baseline to week 56. Full analysis set (FAS=1225) included all randomised subjects who had received at least one dose of semaglutide or sitagliptin.</description>
        <time_frame>Week 0, week 56</time_frame>
        <population>Missing data imputed from a mixed model for repeated measurements for treatment and country as fixed factors and baseline value as covariate, all nested within visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.5 mg + Sitagliptin Placebo</title>
            <description>Semaglutide 0.5 mg administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin placebo (0 mg) administered orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 1.0 mg + Sitagliptin Placebo</title>
            <description>Semaglutide 1.0 mg administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin placebo (0 mg) administered orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin + Semaglutide Placebo</title>
            <description>Subjects were randomised to 2 different placebo arms (sitagliptin + semaglutide placebo 0.5 mg and sitagliptin + semaglutide placebo 1.0 mg). Both arms were pooled together for data analysis. Semaglutide placebo administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin (100 mg) administered orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight From Baseline</title>
          <description>Change in body weight from baseline to week 56. Full analysis set (FAS=1225) included all randomised subjects who had received at least one dose of semaglutide or sitagliptin.</description>
          <population>Missing data imputed from a mixed model for repeated measurements for treatment and country as fixed factors and baseline value as covariate, all nested within visit.</population>
          <units>kilograms</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="409"/>
                <count group_id="O2" value="409"/>
                <count group_id="O3" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.28" spread="0.25"/>
                    <measurement group_id="O2" value="-6.13" spread="0.25"/>
                    <measurement group_id="O3" value="-1.93" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose (FPG) From Baseline</title>
        <description>Change in fasting plasma glucose from baseline to week 56. Full analysis set (FAS=1225) included all randomised subjects who had received at least one dose of semaglutide or sitagliptin.</description>
        <time_frame>Week 0, week 56</time_frame>
        <population>Missing data imputed from a mixed model for repeated measurements for treatment and country as fixed factors and baseline value as covariate, all nested within visit</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.5 mg + Sitagliptin Placebo</title>
            <description>Semaglutide 0.5 mg administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin placebo (0 mg) administered orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 1.0 mg + Sitagliptin Placebo</title>
            <description>Semaglutide 1.0 mg administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin placebo (0 mg) administered orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin + Semaglutide Placebo</title>
            <description>Subjects were randomised to 2 different placebo arms (sitagliptin + semaglutide placebo 0.5 mg and sitagliptin + semaglutide placebo 1.0 mg). Both arms were pooled together for data analysis. Semaglutide placebo administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin (100 mg) administered orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose (FPG) From Baseline</title>
          <description>Change in fasting plasma glucose from baseline to week 56. Full analysis set (FAS=1225) included all randomised subjects who had received at least one dose of semaglutide or sitagliptin.</description>
          <population>Missing data imputed from a mixed model for repeated measurements for treatment and country as fixed factors and baseline value as covariate, all nested within visit</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="409"/>
                <count group_id="O2" value="409"/>
                <count group_id="O3" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.38" spread="1.79"/>
                    <measurement group_id="O2" value="-46.72" spread="1.78"/>
                    <measurement group_id="O3" value="-19.85" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic and Diastolic Blood Pressure From Baseline</title>
        <description>Change in systolic and diastolic blood pressure from baseline to week 56. Full analysis set (FAS=1225) included all randomised subjects who had received at least one dose of semaglutide or sitagliptin</description>
        <time_frame>Week 0, week 56</time_frame>
        <population>Missing data imputed from a mixed model for repeated measurements for treatment and country as fixed factors and baseline value as covariate, all nested within visit</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.5 mg + Sitagliptin Placebo</title>
            <description>Semaglutide 0.5 mg administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin placebo (0 mg) administered orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 1.0 mg + Sitagliptin Placebo</title>
            <description>Semaglutide 1.0 mg administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin placebo (0 mg) administered orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin + Semaglutide Placebo</title>
            <description>Subjects were randomised to 2 different placebo arms (sitagliptin + semaglutide placebo 0.5 mg and sitagliptin + semaglutide placebo 1.0 mg). Both arms were pooled together for data analysis. Semaglutide placebo administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin (100 mg) administered orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic and Diastolic Blood Pressure From Baseline</title>
          <description>Change in systolic and diastolic blood pressure from baseline to week 56. Full analysis set (FAS=1225) included all randomised subjects who had received at least one dose of semaglutide or sitagliptin</description>
          <population>Missing data imputed from a mixed model for repeated measurements for treatment and country as fixed factors and baseline value as covariate, all nested within visit</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="409"/>
                <count group_id="O2" value="409"/>
                <count group_id="O3" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.07" spread="0.64"/>
                    <measurement group_id="O2" value="-5.61" spread="0.63"/>
                    <measurement group_id="O3" value="-2.29" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.01" spread="0.42"/>
                    <measurement group_id="O2" value="-1.91" spread="0.42"/>
                    <measurement group_id="O3" value="-1.11" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Patient Reported Outcome (PRO) Questionnaire Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) From Baseline</title>
        <description>Full analysis set (FAS=1225) included all randomised subjects who had received at least one dose of semaglutide or sitagliptin. The DTSQs questionnaire was used to assess subjects' treatment satisfaction. This questionnaire contained 8 components and evaluates the diabetes treatment (including insulin, tablets and/or diet) in terms of convenience, flexibility and general feelings towards the treatment. The result presented is the 'Treatment Satisfaction' summary score, which is the sum of 6 of the 8 items of the DTSQs questionnaire. Response options range from 6 (best case) to 0 (worst case). Total scores for treatment satisfaction range from 0-36. Higher scores indicate higher satisfaction.</description>
        <time_frame>Week 0, week 56</time_frame>
        <population>Out of the 1225 subjects in FAS, 76 in semaglutide 0.5 mg arm, 76 in semaglutide 1.0 mg arm, and 113 in placebo arm had missing data for the endpoint. Missing data imputed from a mixed model for repeated measurements for treatment and country as fixed factors and baseline value as covariate, all nested within visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.5 mg + Sitagliptin Placebo</title>
            <description>Semaglutide 0.5 mg administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin placebo (0 mg) administered orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 1.0 mg + Sitagliptin Placebo</title>
            <description>Semaglutide 1.0 mg administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin placebo (0 mg) administered orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin + Semaglutide Placebo</title>
            <description>Subjects were randomised to 2 different placebo arms (sitagliptin + semaglutide placebo 0.5 mg and sitagliptin + semaglutide placebo 1.0 mg). Both arms were pooled together for data analysis. Semaglutide placebo administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin (100 mg) administered orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient Reported Outcome (PRO) Questionnaire Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) From Baseline</title>
          <description>Full analysis set (FAS=1225) included all randomised subjects who had received at least one dose of semaglutide or sitagliptin. The DTSQs questionnaire was used to assess subjects' treatment satisfaction. This questionnaire contained 8 components and evaluates the diabetes treatment (including insulin, tablets and/or diet) in terms of convenience, flexibility and general feelings towards the treatment. The result presented is the 'Treatment Satisfaction' summary score, which is the sum of 6 of the 8 items of the DTSQs questionnaire. Response options range from 6 (best case) to 0 (worst case). Total scores for treatment satisfaction range from 0-36. Higher scores indicate higher satisfaction.</description>
          <population>Out of the 1225 subjects in FAS, 76 in semaglutide 0.5 mg arm, 76 in semaglutide 1.0 mg arm, and 113 in placebo arm had missing data for the endpoint. Missing data imputed from a mixed model for repeated measurements for treatment and country as fixed factors and baseline value as covariate, all nested within visit.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="333"/>
                <count group_id="O2" value="333"/>
                <count group_id="O3" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.28" spread="0.23"/>
                    <measurement group_id="O2" value="5.91" spread="0.23"/>
                    <measurement group_id="O3" value="4.45" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Who Achieved HbA1c Below or Equal to 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists (AACE) Target (Yes/no)</title>
        <description>Subjects who achieved HbA1c ≤6.5% (48 mmol/mol) American Association of Clinical Endocrinologists (AACE) target (yes/no) after week 56 weeks of treatment.</description>
        <time_frame>After 56 weeks treatment</time_frame>
        <population>Full analysis set (FAS=1225) included all randomised subjects who had received at least one dose of semaglutide or sitagliptin</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.5 mg + Sitagliptin Placebo</title>
            <description>Semaglutide 0.5 mg administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin placebo (0 mg) administered orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 1.0 mg + Sitagliptin Placebo</title>
            <description>Semaglutide 1.0 mg administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin placebo (0 mg) administered orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin + Semaglutide Placebo</title>
            <description>Subjects were randomised to 2 different placebo arms (sitagliptin + semaglutide placebo 0.5 mg and sitagliptin + semaglutide placebo 1.0 mg). Both arms were pooled together for data analysis. Semaglutide placebo administered subcutaneously (s.c., under the skin) once weekly, in the thigh, abdomen, or upper arm, at any time of day irrespective of meals. Sitagliptin (100 mg) administered orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Who Achieved HbA1c Below or Equal to 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists (AACE) Target (Yes/no)</title>
          <description>Subjects who achieved HbA1c ≤6.5% (48 mmol/mol) American Association of Clinical Endocrinologists (AACE) target (yes/no) after week 56 weeks of treatment.</description>
          <population>Full analysis set (FAS=1225) included all randomised subjects who had received at least one dose of semaglutide or sitagliptin</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="409"/>
                <count group_id="O2" value="409"/>
                <count group_id="O3" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215"/>
                    <measurement group_id="O2" value="270"/>
                    <measurement group_id="O3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194"/>
                    <measurement group_id="O2" value="139"/>
                    <measurement group_id="O3" value="324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are reported for on-treatment period i.e from the date of initiation of trial product to the end of the on-treatment period (up to 56 weeks).</time_frame>
      <desc>Safety analysis set included all subjects exposed to at least one dose of semaglutide or sitagliptin. Number of deaths causally related to treatment is the data considered to present under ‘total number of deaths resulting from adverse events’.</desc>
      <group_list>
        <group group_id="E1">
          <title>Semaglutide 1.0 mg + Sitagliptin Placebo</title>
          <description>Semaglutide 1.0 mg once-weekly + Sitagliptin placebo once-daily</description>
        </group>
        <group group_id="E2">
          <title>Semaglutide 0.5 mg + Sitagliptin Placebo</title>
          <description>Semaglutide 0.5 mg once-weekly + Sitagliptin placebo once-daily</description>
        </group>
        <group group_id="E3">
          <title>Sitagliptin 100 mg + Semaglutide Placebo 1.0 mg</title>
          <description>Sitagliptin 100 mg once-daily + Semaglutide placebo 1.0 mg once-weekly</description>
        </group>
        <group group_id="E4">
          <title>Sitagliptin 100 mg + Semaglutide Placebo 0.5 mg</title>
          <description>Sitagliptin 100 mg once-daily + Semaglutide placebo 0.5 mg once-weekly</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Splenic lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pancreatic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Papilla of Vater stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gas poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Ligamentitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign neoplasm of eyelid</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic unconsciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Glycosuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Ketonuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pharyngeal oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Xanthelasma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoid operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Meniscus operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="197" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="208" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="85" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="29" subjects_affected="23" subjects_at_risk="409"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="409"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="85" subjects_affected="53" subjects_at_risk="409"/>
                <counts group_id="E2" events="91" subjects_affected="53" subjects_at_risk="409"/>
                <counts group_id="E3" events="17" subjects_affected="13" subjects_at_risk="204"/>
                <counts group_id="E4" events="18" subjects_affected="16" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="20" subjects_at_risk="409"/>
                <counts group_id="E2" events="28" subjects_affected="26" subjects_at_risk="409"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="140" subjects_affected="72" subjects_at_risk="409"/>
                <counts group_id="E2" events="110" subjects_affected="73" subjects_at_risk="409"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="204"/>
                <counts group_id="E4" events="23" subjects_affected="17" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="119" subjects_affected="41" subjects_at_risk="409"/>
                <counts group_id="E2" events="49" subjects_affected="33" subjects_at_risk="409"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="204"/>
                <counts group_id="E4" events="9" subjects_affected="5" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="409"/>
                <counts group_id="E2" events="23" subjects_affected="18" subjects_at_risk="409"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="204"/>
                <counts group_id="E4" events="16" subjects_affected="14" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="33" subjects_affected="29" subjects_at_risk="409"/>
                <counts group_id="E2" events="63" subjects_affected="50" subjects_at_risk="409"/>
                <counts group_id="E3" events="20" subjects_affected="19" subjects_at_risk="204"/>
                <counts group_id="E4" events="31" subjects_affected="23" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="409"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="409"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E4" events="16" subjects_affected="13" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="38" subjects_affected="32" subjects_at_risk="409"/>
                <counts group_id="E2" events="41" subjects_affected="33" subjects_at_risk="409"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="204"/>
                <counts group_id="E4" events="17" subjects_affected="16" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="409"/>
                <counts group_id="E2" events="28" subjects_affected="26" subjects_at_risk="409"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="204"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="42" subjects_affected="29" subjects_at_risk="409"/>
                <counts group_id="E2" events="81" subjects_affected="26" subjects_at_risk="409"/>
                <counts group_id="E3" events="19" subjects_affected="9" subjects_at_risk="204"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigators(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>None reported</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Global Clinical Registry (GCR, 1452)</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

